Holen Sie sich die Stockscreener-App
13.75
8.33%
-1.25
Handel nachbörslich:
14.01
0.26
+1.89%
Schlusskurs vom Vortag:
$15.00
Offen:
$14.4
24-Stunden-Volumen:
408.36K
Relative Volume:
0.97
Marktkapitalisierung:
$184.32M
Einnahmen:
$13.11M
Nettoeinkommen (Verlust:
$-124.02M
KGV:
-0.9642
EPS:
-14.261
Netto-Cashflow:
$-107.25M
1W Leistung:
-12.81%
1M Leistung:
-4.71%
6M Leistung:
-43.21%
1J Leistung:
-52.19%
1-Tages-Spanne:
$13.75
$14.98
1-Wochen-Bereich:
$13.75
$17.00
52-Wochen-Spanne:
$13.07
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
13.75 | 201.08M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals Begins Phase 1 Study of Intranasal Oxytocin (TNX-1900) for Migraine and Craniofacial Pain Treatment - Minichart
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain - Bitget
Tonix Pharmaceuticals (TNXP) Advances with Phase 1 Study on TNX-1900 - GuruFocus
Tonix doses first patient in migraine treatment study By Investing.com - Investing.com India
Tonix Pharma Begins Phase 1 Study of TNX-1900 - TipRanks
Tonix (NASDAQ: TNXP) doses first subject in TNX-1900 migraine study - Stock Titan
Q1 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
FY2028 Earnings Estimate for TNXP Issued By Zacks Research - Defense World
Tonix Pharmaceuticals Holding Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
TNXP SEC FilingsTonix Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Why (TNXP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
FY2028 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
Tonix Pharmaceuticals Holding Corp. (TNXP) Presents at BIO-Europe Spring 2026Slideshow - Seeking Alpha
TNXP: ~2500 Patients Have Initiated Treatment with Tonmya Following November 2025 Commercial Launch - Research Tree
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 - The Manila Times
Lyme disease and mpox studies put Tonix on vaccine congress agenda - Stock Titan
Levels Update: What are Tonix Pharmaceuticals Holding Corps earnings expectationsEarnings Performance Report & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Tonix Pharmaceuticals (NASDAQ: TNXP) Seeks 1:2–1:250 Reverse Split; PwC Ratification - Stock Titan
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
Tonix Pharmaceuticals Holding Corp. Trade Ideas — LSX:A40VM0 - TradingView
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Tonix Pharmaceuticals says prescriptions for chronic pain drug top 4,200 since launch - MSN
Tonix Pharma CEO Makes Bold Insider Move Signaling Growing Confidence - TipRanks
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Acquires 15,000 Shares - MarketBeat
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 - Bitget
Tonix Pharmaceuticals (TNXP) CEO adds 15,000 shares in open-market buy - Stock Titan
Tonix Pharmaceuticals Files 8-K Announcing Change in Independent Registered Public Accounting Firm - Minichart
Noble Financial Has Optimistic Outlook of TNXP Q1 Earnings - MarketBeat
Auditor change at Tonix (NASDAQ: TNXP) after going concern warning - Stock Titan
Tonix CEO to spotlight fibromyalgia and Lyme programs in Lisbon - Stock Titan
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 - The Manila Times
Tonix Q4: Revenue Beat, EPS Miss, Early Signs Of Tonmya Momentum (NASDAQ:TNXP) - Seeking Alpha
This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’ - MSN
OTC Markets Hosts Virtual Investor Presentation with Dr. Seth Lederman, Co-Founder, CEO, and Chairman of Tonix Pharmaceuticals, and David Bautz, PhD, Senior Analyst at Zacks SCR - Yahoo Finance
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch - Sahm
Understanding Momentum Shifts in (TNXP) - Stock Traders Daily
Tonix Pharma earnings missed by $0.79, revenue topped estimates - Investing.com South Africa
Tonix Pharmaceuticals reports $13.1M product revenue, $124.0M net loss for FY2025 - TradingView
Tonix Pharmaceuticals (TNXP) Reports Mixed Q4 Results with Reven - GuruFocus
[ARS] Tonix Pharmaceuticals Holding Corp. SEC Filing - Stock Titan
Tonix Pharmaceuticals Q4 Earnings Beat Expectations with Revenue Surge - Intellectia AI
Tonix (TNXP) Sees Transformational Year with FDA Approval and St - GuruFocus
Tonix Pharmaceuticals Wins FDA Approval for TONMYA in Fibromyalgia and Expands CNS, Immunology, and Rare Disease Pipeline - Minichart
Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Quarterly Earnings Results - MarketBeat
Tonix Pharmaceuticals Holding Corp. Announces Successful Launch of TONMYA™ for Fibromyalgia and Provides 2025 Financial Highlights - Quiver Quantitative
Tonix Pharmaceuticals Holding 2025 10-K — Revenue $13.1M, EPS (14.57) - TradingView
First new fibromyalgia drug in 15 years sees 4,200 Tonmya prescriptions - Stock Titan
Aug Chart Watch: What are the future prospects of Tonix Pharmaceuticals Holding CorpTrade Entry Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
TNXP: New fibromyalgia drug launch shows positive uptake; Lyme prevention antibody advances in pipeline - TradingView
Tonix Pharmaceuticals Holding Corp. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):